Piceatannol, a stilbene present in grapes, attenuates dextran sulfate sodium-induced colitis

• Published in: International immunopharmacology 2008-12, Vol.8 (12), p.1695-1702
• Main Authors: Kim, Yoon Hee, Kwon, Hyuck-Se, Kim, Dae Hwan, Cho, Han Jin, Lee, Hyun Suck, Jun, Jong-Gab, Park, Jung Han Yoon, Kim, Jin-Kyung
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Colitis - chemically induced; Colitis - drug therapy; Colitis - immunology; Colitis - pathology; Colon - immunology; Cytokines; Dextran Sulfate - toxicity; Dextran sulfate sodium; Female; Gastroenterology. Liver. Pancreas. Abdomen; Immunohistochemistry; Inflammation; Inflammation Mediators - metabolism; Inflammatory bowel disease; Medical sciences; Mice; Mice, Inbred BALB C; NF-kappa B - analysis; Other diseases. Semiology; Peroxidase - metabolism; Pharmacology. Drug treatments; Piceatannol; STAT3 Transcription Factor - analysis; Stilbenes - therapeutic use; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Vitaceae; Vitis - chemistry
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2008.08.003

Piceatannol (3,5,3',4'-tetrahydroxy-trans-stilbene; PIC) is a polyphenol found in grapes. It is known as a protein kinase inhibitor that modifies multiple cellular targets, exerting immunosuppressive and antitumorigenic activities in several cell lines. The purpose of the present work was to evaluate the anti-inflammatory effect of PIC on dextran sulfate sodium (DSS)-induced colitis. Experimental colitis was induced in BALB/c mice by dissolving 5% DSS in their drinking water for 7 days. PIC (1, 2.5, 5, or 10 mg/kg body weight) was administrated daily per oral route for 7 days. A significant blunting of weight loss and clinical signs was observed in DSS-exposed, PIC-treated mice when compared to vehicle-treated mice. This was associated with a remarkable amelioration of the disruption of the colonic architecture, a significant reduction in colonic myeloperoxidase (MPO) activity, and a decrease in production of inflammatory mediators such as nitric oxide (NO), prostaglandin (PG) E 2, and pro-inflammatory cytokines. The present data indicate that further evaluation of the potential of PIC as an agent for the prevention and/or treatment of inflammatory bowel diseases in human clinical studies is warranted.